Skip Navigation
MUSC 
 
About FRD
    For Inventorsfor IndustryFor Entrprenuers
Inventors Introduction
 
Industry Introduction
Information and Resources
Agreements
Frequently Asked Questions
Available Technologies
 Entrepreneurs Introduction 
  
 Start-Up Resources 
   
     
  • The invention provides for a novel approach of treating lung fibrosis related diseases (including scleroderma lung disease, idiopathic pulmonary fibrosis, interstitial pneumonia, asbestosis). Currently, there are no effective treatments available for these diseases.  Upregulation of caveolin-1 was achieved by either infecting cells with adenovirus encoding the full-length caveolin-1 molecule or using a membrane-permeable peptide containing the caveolin-1 scaffolding domain (CSD).  Control bleomycin-treated mice showed severe lung damage, whereas mice receiving CSD showed only slight to moderate lung damage. Pre-clinical data indicates that CSD peptide provides protection against the progression of lung fibrosis through several distinct mechanisms. A variety of insults trigger a common pathway that culminates in lung fibrosis. The inventors have shown the ability of caveolin-1 to block these processes.

     

     

     
  • Researchers at MUSC have developed a urinary biomarker to identify, diagnose, and monitor renal mitochondrial dysfunction. Mitochondrial dysfunction leads to cellular dysfunction and can ultimately lead to cell death in organs such as the heart, brain, lungs, liver, and kidney; thus there is a great need for non-invasive biomarkers to detect mitochondrial dysfunction. Researchers have identified a protein in urine that is a sensitive and specific biomarker of mitochondrial dysfunction in patients with acute kidney injury (AKI) following cardiac surgery compared to patients with no AKI following cardiac surgery and healthy controls. Additionally, this urinary protein was increased in rats under both ischemia/reperfusion-induced AKI and glycerol-induced AKI when renal mitochondrial dysfunction was present. The studies represent new urinary biomarkers of renal mitochondrial dysfunction in human and animals that can readily be translated into laboratory and clinical practice.

     

  • Researchers at MUSC have developed a high-throughput assay that uses fluorescence polarization (FP) to distinguish the fluorescent penicillin, Bocillin-FL, in free or PBP-bound form.  The assay can be used to identify new compounds that inhibit penicillin binding proteins (PBPs), which are proven targets for ?-lactam antibiotics. This assay was used to screen a 50,000 compound library for potential inhibitors of N. gonorrhoeae PBP 2. As a result, 32 compounds were identified that exhibited >50% inhibition of Bocillin-FL binding to PBP 2. These included a cephalosporin that provided validation of the assay. This assay paves the way for more comprehensive high-throughput screening of compound libraries for non-?-lactam antimicrobial compounds.
     
     
  •  
    Researchers at MUSC have identified a specific fragment of the mesenchymal-epithelial transition factor (MET) receptor as a peptide with robust antifibrotic properties. Preliminary studies show that the purified peptide markedly reduces collagen and other extracellular matrix proteins in scleroderma lung fibroblasts and in TGF-?-stimulated normal lung fibroblasts.
     
  •  
     
     
     
     
     
    Join us as we unlock imaging in the service of health and medicine!
    Educational Library, Room 120
     
    For more information see here or contact Olivia Urig at urig@musc.edu or 843-876-1900. 
View All TechnologiesFollow Us on LinkedIn!
 
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Harborview Office Tower, 19 Hagood Avenue, Suite 909, Charleston, SC 29403    Ph. 843.876.1900  Fx. 843.876.1905